董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Grigorios Siokas | 男 | Chairman, Chief Executive Officer and Director | 60 | 355.23万美元 | 1327.43 | 2026-07-15 |
| Demetrios G. Demetriades | 男 | Director and Secretary | 58 | 2.25万美元 | 6.50 | 2026-07-15 |
| John J. Hoidas | 男 | Director | 59 | 2.25万美元 | 10.00 | 2026-07-15 |
| Suhel Bhutawala | 男 | Director | 47 | 8.39万美元 | 5.00 | 2026-07-15 |
| Theodoros C. Karkantzos | 男 | Director | 38 | 2.25万美元 | 2.00 | 2026-07-15 |
| Anastasios Aslidis | 男 | Director | 65 | 5.00万美元 | 5.50 | 2026-07-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Grigorios Siokas | 男 | Chairman, Chief Executive Officer and Director | 60 | 355.23万美元 | 1327.43 | 2026-07-15 |
| Demetrios G. Demetriades | 男 | Director and Secretary | 58 | 2.25万美元 | 6.50 | 2026-07-15 |
| Georgios Terzis | 男 | Chief Financial Officer | 44 | 59.23万美元 | 206.73 | 2026-07-15 |
| Nikolaos Bardakis | 男 | Chief Operating Officer | 57 | 3.94万美元 | 4.50 | 2026-07-15 |
董事简历
中英对照 | 中文 | 英文- Grigorios Siokas
-
Grigorios Siokas于2016年2月26日加入Cosmos Holdings，担任首席执行官、CFO兼董事。于2020年11月11日，他辞去代理CFO的职务。他在制药行业有超过15年的经验。自2014年起，他担任公司全资子公司SkyPharm SA的首席执行官和运营经理。SkyPharm公司是一家位于希腊的制药公司，主要从希腊向德国、英国和丹麦等其他欧洲国家出口药品。2014年之前，Siokas先生在制药工业的多个部门工作，主要从事希腊和其他欧洲国家的药品贸易。此外，自2000年以来，他一直是多家制药公司的大股东，如：Ippokratis制药公司（年销售额超过7800万欧元）；Thrakis制药公司（年销售额超过2000万欧元）；Thessalias制药公司（年销售额超过1800万欧元）；ZED制药公司（年销售额超过3500万欧元）。上世纪90年代，西奥卡斯先生在德国创立并经营一家大理石批发进出口公司。在两年内，他成为德国第四大希腊大理石进口商。他还与许多不同的航空公司合作经营旅游业务，为数百万客户提供服务。Grigorios Siokas拥有希腊塞萨洛尼基亚里士多德大学地质学学士学位。他在德国斯图加特大学和图比根大学获得管理和金融硕士学位。
Grigorios Siokas joined Cosmos Health, Inc. as CEO, CFO and Director on February 26, 2016. He relinquished his position as acting CFO on November 11, 2020. He has over [15] years' experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark. Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over 78 million); Thrakis Pharmaceuticals, (annual sales of over 20 million); Thessalias Pharmaceuticals, (annual sales of over 18 million); and ZED Pharma SA, (annual sales of over 35 million). During the 1990s, Mr. Siokas founded and operated a marble wholesale import export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers. Grigorios Siokas has a Bachelor's Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master's in management and finance from the University of Stuttgart and the University of Tuebigen, Germany. - Grigorios Siokas于2016年2月26日加入Cosmos Holdings，担任首席执行官、CFO兼董事。于2020年11月11日，他辞去代理CFO的职务。他在制药行业有超过15年的经验。自2014年起，他担任公司全资子公司SkyPharm SA的首席执行官和运营经理。SkyPharm公司是一家位于希腊的制药公司，主要从希腊向德国、英国和丹麦等其他欧洲国家出口药品。2014年之前，Siokas先生在制药工业的多个部门工作，主要从事希腊和其他欧洲国家的药品贸易。此外，自2000年以来，他一直是多家制药公司的大股东，如：Ippokratis制药公司（年销售额超过7800万欧元）；Thrakis制药公司（年销售额超过2000万欧元）；Thessalias制药公司（年销售额超过1800万欧元）；ZED制药公司（年销售额超过3500万欧元）。上世纪90年代，西奥卡斯先生在德国创立并经营一家大理石批发进出口公司。在两年内，他成为德国第四大希腊大理石进口商。他还与许多不同的航空公司合作经营旅游业务，为数百万客户提供服务。Grigorios Siokas拥有希腊塞萨洛尼基亚里士多德大学地质学学士学位。他在德国斯图加特大学和图比根大学获得管理和金融硕士学位。
- Grigorios Siokas joined Cosmos Health, Inc. as CEO, CFO and Director on February 26, 2016. He relinquished his position as acting CFO on November 11, 2020. He has over [15] years' experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark. Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over 78 million); Thrakis Pharmaceuticals, (annual sales of over 20 million); Thessalias Pharmaceuticals, (annual sales of over 18 million); and ZED Pharma SA, (annual sales of over 35 million). During the 1990s, Mr. Siokas founded and operated a marble wholesale import export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers. Grigorios Siokas has a Bachelor's Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master's in management and finance from the University of Stuttgart and the University of Tuebigen, Germany.
- Demetrios G. Demetriades
-
Demetrios G. Demetriades获选为公司秘书及董事，自2014年1月13日起生效。自2003年1月以来，Demetriades先生一直担任贸易公司Highlander Spring Trading Ltd的董事。2000年11月至2002年12月，他担任Eurolink证券有限公司的营销总监，该公司参与塞浦路斯证券交易所的交易。1995年1月至2000年11月，他担任融资公司Laiki Factors Ltd的主管。根据董事会的决定，Demetriades先生将不时获得服务报酬。他还在2021财政年度担任审计委员会成员。
Demetrios G. Demetriades was elected as Member of the Company's Board of Directors effective January 13, 2014. Since January 2003, Mr. Demetriades has been Director of Highlander Spring Trading Ltd, a trading company. From November 2000 to December 2002, he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange. From January 1995 to November 2000, he was Supervising Officer of Laiki Factors Ltd a financing company. Mr. Demetriades will be compensated for his service from time to time as the Board of Directors will determine. He was also on the Audit Committee during the fiscal year 2021. - Demetrios G. Demetriades获选为公司秘书及董事，自2014年1月13日起生效。自2003年1月以来，Demetriades先生一直担任贸易公司Highlander Spring Trading Ltd的董事。2000年11月至2002年12月，他担任Eurolink证券有限公司的营销总监，该公司参与塞浦路斯证券交易所的交易。1995年1月至2000年11月，他担任融资公司Laiki Factors Ltd的主管。根据董事会的决定，Demetriades先生将不时获得服务报酬。他还在2021财政年度担任审计委员会成员。
- Demetrios G. Demetriades was elected as Member of the Company's Board of Directors effective January 13, 2014. Since January 2003, Mr. Demetriades has been Director of Highlander Spring Trading Ltd, a trading company. From November 2000 to December 2002, he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange. From January 1995 to November 2000, he was Supervising Officer of Laiki Factors Ltd a financing company. Mr. Demetriades will be compensated for his service from time to time as the Board of Directors will determine. He was also on the Audit Committee during the fiscal year 2021.
- John J. Hoidas
-
John J. Hoidas于2016年11月18日被任命为公司董事会成员，并成为公司第四位董事会成员。他目前是总部在芝加哥的Uhlmann Price证券公司的高级副总裁。在过去的几年里，他成功地为Organovo（ONVO）、Invivo Therapeutics（NVIV）和Matinas BioPharma（MTNB）等处于IPO前的晚期公司筹集了大量资金。他曾担任以下公司的经纪交易商：Kingsbury Capital Investment Advisors、Kingsbury Capital LLC、Spencer Trask Ventures。他还在2021财政年度担任审计委员会成员。
John J. Hoidas was appointed a Member of the Company's Board of Directors on November 18, 2016 and he became the fourth member of the Board of Directors of the Company. He is currently the senior vice president of Uhlmann Price Securities based in Chicago. Over the previous years he achieved to raise significant amounts of capital for late stage pre IPO companies such as Organovo ("ONVO"), Invivo Therapeutics ("NVIV") and Matinas BioPharma ("MTNB") to name a few. He has served as a broker dealer to the following firms: Kingsbury Capital Investment Advisors, Kingsbury Capital LLC, Spencer Trask Ventures. He was also on the Audit Committee during the fiscal year 2021. - John J. Hoidas于2016年11月18日被任命为公司董事会成员，并成为公司第四位董事会成员。他目前是总部在芝加哥的Uhlmann Price证券公司的高级副总裁。在过去的几年里，他成功地为Organovo（ONVO）、Invivo Therapeutics（NVIV）和Matinas BioPharma（MTNB）等处于IPO前的晚期公司筹集了大量资金。他曾担任以下公司的经纪交易商：Kingsbury Capital Investment Advisors、Kingsbury Capital LLC、Spencer Trask Ventures。他还在2021财政年度担任审计委员会成员。
- John J. Hoidas was appointed a Member of the Company's Board of Directors on November 18, 2016 and he became the fourth member of the Board of Directors of the Company. He is currently the senior vice president of Uhlmann Price Securities based in Chicago. Over the previous years he achieved to raise significant amounts of capital for late stage pre IPO companies such as Organovo ("ONVO"), Invivo Therapeutics ("NVIV") and Matinas BioPharma ("MTNB") to name a few. He has served as a broker dealer to the following firms: Kingsbury Capital Investment Advisors, Kingsbury Capital LLC, Spencer Trask Ventures. He was also on the Audit Committee during the fiscal year 2021.
- Suhel Bhutawala
-
Suhel Bhutawala，于2023年9月18日被任命为公司董事会成员。布塔瓦拉先生有化学背景。Bhutawala先生自2017年4月起担任公司子公司英国哈洛Decahedron Ltd的董事总经理。2015年5月至2017年3月，他在伦敦的Chemilines Ltd担任商务经理，负责采购、销售和私人调查员（PI）团队协助。2009年12月至2015年5月，Bhutawala先生在伦敦纽兰兹药房担任药房经理和采购员。2005年9月至2009年11月，他在伦敦Alliance Boots担任高级药房配药员。Bhutawala先生在印度北马哈拉施特拉邦大学获得药学学士学位，在伦敦国王学院获得药物分析和质量控制、法规事务理学硕士学位。
Suhel Bhutawala was appointed a Member of the Company's Board of Directors on September 18, 2023. Mr. Bhutawala has a background in chemistry. Mr. Bhutawala has been a managing director of Decahedron Ltd in Harlow, U.K., the company's subsidiary, since April 2017. From May 2015 to March 2017, he was commercial manager, in relation to procurements, sales and Private Investigator (PI) team assistance, at Chemilines Ltd in London. From December 2009 to May 2015, Mr. Bhutawala served as pharmacy manager and buyer at Newlands Pharmacy in London. From early 2005 to November 2009, he was senior pharmacy dispenser at Alliance Boots in London. Mr. Bhutawala received a Bachelor of Pharmacy from North Maharashtra University, India and a MSc in Pharmaceutical Analysis and Quality control, Regulatory Affairs from King's college of London. - Suhel Bhutawala，于2023年9月18日被任命为公司董事会成员。布塔瓦拉先生有化学背景。Bhutawala先生自2017年4月起担任公司子公司英国哈洛Decahedron Ltd的董事总经理。2015年5月至2017年3月，他在伦敦的Chemilines Ltd担任商务经理，负责采购、销售和私人调查员（PI）团队协助。2009年12月至2015年5月，Bhutawala先生在伦敦纽兰兹药房担任药房经理和采购员。2005年9月至2009年11月，他在伦敦Alliance Boots担任高级药房配药员。Bhutawala先生在印度北马哈拉施特拉邦大学获得药学学士学位，在伦敦国王学院获得药物分析和质量控制、法规事务理学硕士学位。
- Suhel Bhutawala was appointed a Member of the Company's Board of Directors on September 18, 2023. Mr. Bhutawala has a background in chemistry. Mr. Bhutawala has been a managing director of Decahedron Ltd in Harlow, U.K., the company's subsidiary, since April 2017. From May 2015 to March 2017, he was commercial manager, in relation to procurements, sales and Private Investigator (PI) team assistance, at Chemilines Ltd in London. From December 2009 to May 2015, Mr. Bhutawala served as pharmacy manager and buyer at Newlands Pharmacy in London. From early 2005 to November 2009, he was senior pharmacy dispenser at Alliance Boots in London. Mr. Bhutawala received a Bachelor of Pharmacy from North Maharashtra University, India and a MSc in Pharmaceutical Analysis and Quality control, Regulatory Affairs from King's college of London.
- Theodoros C. Karkantzos
-
Theodoros C. Karkantzos是全球数字营销和企业传播公司Blue Dot Digital Agency的联合创始人，也是一家专注于房地产、医疗保健、股票和酒店业的私人投资者。他的专长涵盖金融、战略、私募股权和资产管理，通过在欧洲各地的创业和领导角色发展而来。他拥有剑桥大学房地产金融硕士学位，以优异成绩毕业并获得Alister Ross-Goobey最佳综合表现奖和皇家特许测量师学会房地产投资和风险分析奖。他还拥有华威大学管理学学士学位，以一级荣誉毕业。
Theodoros C. Karkantzos was elected to serve on the Company's Board of Directors at the Annual General Meeting held on September 30, 2025, replacing Manfred Ziegler. Mr. Karkantzos has over 15 years of experience in investment and business development. He is the Co Founder of Blue Dot Digital Agency, a global digital marketing and corporate communications firm, and is also a private investor with a focus on real estate, healthcare, equities, and hospitality sectors. His expertise spans finance, strategy, private equity, and asset management, developed through both entrepreneurial ventures and senior leadership roles across Europe. - Theodoros C. Karkantzos是全球数字营销和企业传播公司Blue Dot Digital Agency的联合创始人，也是一家专注于房地产、医疗保健、股票和酒店业的私人投资者。他的专长涵盖金融、战略、私募股权和资产管理，通过在欧洲各地的创业和领导角色发展而来。他拥有剑桥大学房地产金融硕士学位，以优异成绩毕业并获得Alister Ross-Goobey最佳综合表现奖和皇家特许测量师学会房地产投资和风险分析奖。他还拥有华威大学管理学学士学位，以一级荣誉毕业。
- Theodoros C. Karkantzos was elected to serve on the Company's Board of Directors at the Annual General Meeting held on September 30, 2025, replacing Manfred Ziegler. Mr. Karkantzos has over 15 years of experience in investment and business development. He is the Co Founder of Blue Dot Digital Agency, a global digital marketing and corporate communications firm, and is also a private investor with a focus on real estate, healthcare, equities, and hospitality sectors. His expertise spans finance, strategy, private equity, and asset management, developed through both entrepreneurial ventures and senior leadership roles across Europe.
- Anastasios Aslidis
-
Anastasios Aslidis自2005年9月起担任Euroseas Ltd.首席财务官兼财务主任兼Euroseas有限公司董事会成员。在加入Euroseas公司之前，Aslidis博士是Marsoft公司的合伙人，该公司是一家专注于海运业投资和风险管理的国际咨询公司。Aslidis博士在海运行业拥有超过25年的经验。他还曾担任公共和私人航运公司董事会的顾问，就战略发展、资产选择和投资时机提供咨询。Aslidis博士拥有1989年麻省理工学院海洋系统管理博士学位、1987年运筹学硕士学位和1984年麻省理工学院海洋系统管理硕士学位，以及1983年雅典国立技术大学海军建筑和海洋工程文凭。
Anastasios Aslidis was appointed a Member of the Company's Board of Directors and as a Member of the Audit Committee of the Board of Directors on April 29, 2022. Dr. Aslidis is currently, and has been since May 5, 2018, the Chief Financial Officer and Treasurer and a member of the Board of Directors of EuroDry (Nasdaq: EDRY). He is also member of the Board of Directors, Treasurer and Chief Financial Officer of Euroseas since August, 2005. (Nasdaq: ESEA). Prior to joining Euroseas, Dr. Aslidis was a partner at Marsoft Inc., an international consulting firm focusing on investment and risk management in the maritime industry. Dr. Aslidis has more than 30 years of experience in the maritime industry. He also served as consultant to the Boards of Directors of companies (public and private) advising on strategy development, asset selection and investment timing. Dr. Aslidis holds a Ph.D. in Ocean Systems Management (1989) from the Massachusetts Institute of Technology, M.S. in Operations Research (1987) and M.S. in Ocean Systems Management (1984) also from the Massachusetts Institute of Technology, and a Diploma in Naval Architecture and Marine Engineering from the National Technical University of Athens (1983). - Anastasios Aslidis自2005年9月起担任Euroseas Ltd.首席财务官兼财务主任兼Euroseas有限公司董事会成员。在加入Euroseas公司之前，Aslidis博士是Marsoft公司的合伙人，该公司是一家专注于海运业投资和风险管理的国际咨询公司。Aslidis博士在海运行业拥有超过25年的经验。他还曾担任公共和私人航运公司董事会的顾问，就战略发展、资产选择和投资时机提供咨询。Aslidis博士拥有1989年麻省理工学院海洋系统管理博士学位、1987年运筹学硕士学位和1984年麻省理工学院海洋系统管理硕士学位，以及1983年雅典国立技术大学海军建筑和海洋工程文凭。
- Anastasios Aslidis was appointed a Member of the Company's Board of Directors and as a Member of the Audit Committee of the Board of Directors on April 29, 2022. Dr. Aslidis is currently, and has been since May 5, 2018, the Chief Financial Officer and Treasurer and a member of the Board of Directors of EuroDry (Nasdaq: EDRY). He is also member of the Board of Directors, Treasurer and Chief Financial Officer of Euroseas since August, 2005. (Nasdaq: ESEA). Prior to joining Euroseas, Dr. Aslidis was a partner at Marsoft Inc., an international consulting firm focusing on investment and risk management in the maritime industry. Dr. Aslidis has more than 30 years of experience in the maritime industry. He also served as consultant to the Boards of Directors of companies (public and private) advising on strategy development, asset selection and investment timing. Dr. Aslidis holds a Ph.D. in Ocean Systems Management (1989) from the Massachusetts Institute of Technology, M.S. in Operations Research (1987) and M.S. in Ocean Systems Management (1984) also from the Massachusetts Institute of Technology, and a Diploma in Naval Architecture and Marine Engineering from the National Technical University of Athens (1983).
高管简历
中英对照 | 中文 | 英文- Grigorios Siokas
Grigorios Siokas于2016年2月26日加入Cosmos Holdings，担任首席执行官、CFO兼董事。于2020年11月11日，他辞去代理CFO的职务。他在制药行业有超过15年的经验。自2014年起，他担任公司全资子公司SkyPharm SA的首席执行官和运营经理。SkyPharm公司是一家位于希腊的制药公司，主要从希腊向德国、英国和丹麦等其他欧洲国家出口药品。2014年之前，Siokas先生在制药工业的多个部门工作，主要从事希腊和其他欧洲国家的药品贸易。此外，自2000年以来，他一直是多家制药公司的大股东，如：Ippokratis制药公司（年销售额超过7800万欧元）；Thrakis制药公司（年销售额超过2000万欧元）；Thessalias制药公司（年销售额超过1800万欧元）；ZED制药公司（年销售额超过3500万欧元）。上世纪90年代，西奥卡斯先生在德国创立并经营一家大理石批发进出口公司。在两年内，他成为德国第四大希腊大理石进口商。他还与许多不同的航空公司合作经营旅游业务，为数百万客户提供服务。Grigorios Siokas拥有希腊塞萨洛尼基亚里士多德大学地质学学士学位。他在德国斯图加特大学和图比根大学获得管理和金融硕士学位。
Grigorios Siokas joined Cosmos Health, Inc. as CEO, CFO and Director on February 26, 2016. He relinquished his position as acting CFO on November 11, 2020. He has over [15] years' experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark. Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over 78 million); Thrakis Pharmaceuticals, (annual sales of over 20 million); Thessalias Pharmaceuticals, (annual sales of over 18 million); and ZED Pharma SA, (annual sales of over 35 million). During the 1990s, Mr. Siokas founded and operated a marble wholesale import export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers. Grigorios Siokas has a Bachelor's Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master's in management and finance from the University of Stuttgart and the University of Tuebigen, Germany.- Grigorios Siokas于2016年2月26日加入Cosmos Holdings，担任首席执行官、CFO兼董事。于2020年11月11日，他辞去代理CFO的职务。他在制药行业有超过15年的经验。自2014年起，他担任公司全资子公司SkyPharm SA的首席执行官和运营经理。SkyPharm公司是一家位于希腊的制药公司，主要从希腊向德国、英国和丹麦等其他欧洲国家出口药品。2014年之前，Siokas先生在制药工业的多个部门工作，主要从事希腊和其他欧洲国家的药品贸易。此外，自2000年以来，他一直是多家制药公司的大股东，如：Ippokratis制药公司（年销售额超过7800万欧元）；Thrakis制药公司（年销售额超过2000万欧元）；Thessalias制药公司（年销售额超过1800万欧元）；ZED制药公司（年销售额超过3500万欧元）。上世纪90年代，西奥卡斯先生在德国创立并经营一家大理石批发进出口公司。在两年内，他成为德国第四大希腊大理石进口商。他还与许多不同的航空公司合作经营旅游业务，为数百万客户提供服务。Grigorios Siokas拥有希腊塞萨洛尼基亚里士多德大学地质学学士学位。他在德国斯图加特大学和图比根大学获得管理和金融硕士学位。
- Grigorios Siokas joined Cosmos Health, Inc. as CEO, CFO and Director on February 26, 2016. He relinquished his position as acting CFO on November 11, 2020. He has over [15] years' experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark. Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over 78 million); Thrakis Pharmaceuticals, (annual sales of over 20 million); Thessalias Pharmaceuticals, (annual sales of over 18 million); and ZED Pharma SA, (annual sales of over 35 million). During the 1990s, Mr. Siokas founded and operated a marble wholesale import export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers. Grigorios Siokas has a Bachelor's Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master's in management and finance from the University of Stuttgart and the University of Tuebigen, Germany.
- Demetrios G. Demetriades
Demetrios G. Demetriades获选为公司秘书及董事，自2014年1月13日起生效。自2003年1月以来，Demetriades先生一直担任贸易公司Highlander Spring Trading Ltd的董事。2000年11月至2002年12月，他担任Eurolink证券有限公司的营销总监，该公司参与塞浦路斯证券交易所的交易。1995年1月至2000年11月，他担任融资公司Laiki Factors Ltd的主管。根据董事会的决定，Demetriades先生将不时获得服务报酬。他还在2021财政年度担任审计委员会成员。
Demetrios G. Demetriades was elected as Member of the Company's Board of Directors effective January 13, 2014. Since January 2003, Mr. Demetriades has been Director of Highlander Spring Trading Ltd, a trading company. From November 2000 to December 2002, he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange. From January 1995 to November 2000, he was Supervising Officer of Laiki Factors Ltd a financing company. Mr. Demetriades will be compensated for his service from time to time as the Board of Directors will determine. He was also on the Audit Committee during the fiscal year 2021.- Demetrios G. Demetriades获选为公司秘书及董事，自2014年1月13日起生效。自2003年1月以来，Demetriades先生一直担任贸易公司Highlander Spring Trading Ltd的董事。2000年11月至2002年12月，他担任Eurolink证券有限公司的营销总监，该公司参与塞浦路斯证券交易所的交易。1995年1月至2000年11月，他担任融资公司Laiki Factors Ltd的主管。根据董事会的决定，Demetriades先生将不时获得服务报酬。他还在2021财政年度担任审计委员会成员。
- Demetrios G. Demetriades was elected as Member of the Company's Board of Directors effective January 13, 2014. Since January 2003, Mr. Demetriades has been Director of Highlander Spring Trading Ltd, a trading company. From November 2000 to December 2002, he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange. From January 1995 to November 2000, he was Supervising Officer of Laiki Factors Ltd a financing company. Mr. Demetriades will be compensated for his service from time to time as the Board of Directors will determine. He was also on the Audit Committee during the fiscal year 2021.
- Georgios Terzis
Georgios Terzis于2020年11月11日当选为CFO。在此之前，自2017年1月1日起，他被公司聘为国际财务经理。他曾担任多家跨国咨询公司的执行顾问，在那里他实现了超过5000万欧元的资金、融资和国家奖励的承诺，对医疗保健、物流、RES和制造业进行了大量投资。George拥有Alba研究生院的工商管理硕士学位和阿提卡大学的财务管理学士学位。他被欧洲联盟委员会认证为公司和私人投资的独立估价师。
Georgios Terzis was elected Chief Financial Officer on November 11, 2020. Prior thereto, from January 1, 2017, he was employed by the Company as International Finance Manager. He has served as an Executive Consultant to several multinational advisory firms where, he achieved commitments of more than 50 million funding, financing and state incentives to a numerus investment in healthcare, logistics, RES and manufacturing industries. George holds an MBA from Alba Graduate Business school and a Bachelor's Degree in Financial Management from University of Attica. He is certified as an independent valuator of companies and private investments by the European Commission.- Georgios Terzis于2020年11月11日当选为CFO。在此之前，自2017年1月1日起，他被公司聘为国际财务经理。他曾担任多家跨国咨询公司的执行顾问，在那里他实现了超过5000万欧元的资金、融资和国家奖励的承诺，对医疗保健、物流、RES和制造业进行了大量投资。George拥有Alba研究生院的工商管理硕士学位和阿提卡大学的财务管理学士学位。他被欧洲联盟委员会认证为公司和私人投资的独立估价师。
- Georgios Terzis was elected Chief Financial Officer on November 11, 2020. Prior thereto, from January 1, 2017, he was employed by the Company as International Finance Manager. He has served as an Executive Consultant to several multinational advisory firms where, he achieved commitments of more than 50 million funding, financing and state incentives to a numerus investment in healthcare, logistics, RES and manufacturing industries. George holds an MBA from Alba Graduate Business school and a Bachelor's Degree in Financial Management from University of Attica. He is certified as an independent valuator of companies and private investments by the European Commission.
- Nikolaos Bardakis
Nikolaos Bardakis于2023年2月1日被任命为首席运营官，接替Pavlos Ignatiades。巴尔达基斯曾在专注于心血管、中枢神经系统和代谢疾病领域的跨国制药公司Servier Hellas担任全国销售总监超过11年，在那里他领导了一个以客户为中心的跨职能团队，由销售、贸易、营销和业务发展人员组成，管理着130多名员工。他获得了国际曝光度，参加了几次以欧洲一级设计和发射项目为重点的董事会和会议，在国际业务方面具有开创性。巴尔达基斯先生在希腊美国学院获得了金融学学士学位，同时还获得了自然科学方面的相关研究。
Nikolaos Bardakis was, for more than 11 years, the National Sales Director for Servier Hellas, a multinational pharmaceutical company specializing in the areas of Cardiovascular, Central Nervous System and Metabolic diseases, where he led a cross functional client focused team comprised of Sales, Trade, Marketing and Business Development personnel, managing over 130 employees. He gained international exposure, participating in several boards and meetings focused on European level design and launch projects, pioneering in international operations. Mr. Bardakis received a BS in Finance from American College of Greece along with relevant studies in Natural Sciences.- Nikolaos Bardakis于2023年2月1日被任命为首席运营官，接替Pavlos Ignatiades。巴尔达基斯曾在专注于心血管、中枢神经系统和代谢疾病领域的跨国制药公司Servier Hellas担任全国销售总监超过11年，在那里他领导了一个以客户为中心的跨职能团队，由销售、贸易、营销和业务发展人员组成，管理着130多名员工。他获得了国际曝光度，参加了几次以欧洲一级设计和发射项目为重点的董事会和会议，在国际业务方面具有开创性。巴尔达基斯先生在希腊美国学院获得了金融学学士学位，同时还获得了自然科学方面的相关研究。
- Nikolaos Bardakis was, for more than 11 years, the National Sales Director for Servier Hellas, a multinational pharmaceutical company specializing in the areas of Cardiovascular, Central Nervous System and Metabolic diseases, where he led a cross functional client focused team comprised of Sales, Trade, Marketing and Business Development personnel, managing over 130 employees. He gained international exposure, participating in several boards and meetings focused on European level design and launch projects, pioneering in international operations. Mr. Bardakis received a BS in Finance from American College of Greece along with relevant studies in Natural Sciences.